Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by Korea Investment CORP

Korea Investment CORP lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,581 shares of the biopharmaceutical company’s stock after selling 3,410 shares during the period. Korea Investment CORP’s holdings in Regeneron Pharmaceuticals were worth $8,755,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of REGN. Fieldpoint Private Securities LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $130,000. Sterling Investment Advisors Ltd. raised its position in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the last quarter. FNY Partners Fund LP raised its position in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the last quarter. Alpha Windward LLC raised its position in Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares during the last quarter. Finally, IFP Advisors Inc raised its position in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 96 shares during the last quarter. Institutional investors own 67.57% of the company’s stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.82 earnings per share.

TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by Korea Investment CORP” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/11/02/regeneron-pharmaceuticals-inc-regn-shares-sold-by-korea-investment-corp.html.

REGN has been the subject of several research analyst reports. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Robert W. Baird cut shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price objective for the company. in a research report on Tuesday, August 1st. Jefferies Group LLC restated a “hold” rating and issued a $500.00 price objective (up previously from $471.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, September 29th. Finally, Credit Suisse Group cut shares of Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price objective for the company. in a research report on Friday, July 14th. Four investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $488.57.

In other news, Director Charles A. Baker sold 2,000 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at $4,950,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The disclosure for this sale can be found here. Insiders have sold 89,468 shares of company stock valued at $42,312,448 in the last ninety days. Insiders own 10.80% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply